> top > docs > PMC:7558914 > spans > 20753-23670 > annotations

PMC:7558914 / 20753-23670 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id
530 1442-1464 Gene denotes interleukin 6 receptor Gene:3570
531 398-406 Species denotes patients Tax:9606
532 418-425 Species denotes patient Tax:9606
533 569-577 Species denotes patients Tax:9606
534 804-812 Species denotes patients Tax:9606
535 1632-1640 Species denotes patients Tax:9606
536 1765-1773 Species denotes patients Tax:9606
537 2389-2397 Species denotes patients Tax:9606
538 756-774 Chemical denotes methylprednisolone MESH:D008775
539 920-938 Chemical denotes Methylprednisolone MESH:D008775
540 1133-1146 Chemical denotes dexamethasone MESH:D003907
541 1204-1214 Chemical denotes prednisone MESH:D011241
542 1421-1432 Chemical denotes Tocilizumab MESH:C502936
543 1717-1728 Chemical denotes tocilizumab MESH:C502936
544 1913-1924 Chemical denotes tocilizumab MESH:C502936
545 2122-2133 Chemical denotes tocilizumab MESH:C502936
546 27-31 Disease denotes ARDS MESH:D012128
547 296-315 Disease denotes secondary infection MESH:D060085
548 321-334 Disease denotes hyperglycemia MESH:D006943
549 389-397 Disease denotes COVID-19 MESH:C000657245
550 583-601 Disease denotes COVID-19 pneumonia MESH:C000657245
551 661-670 Disease denotes mortality MESH:D003643
552 825-833 Disease denotes COVID-19 MESH:C000657245
553 838-842 Disease denotes ARDS MESH:D012128
554 1406-1414 Disease denotes COVID-19 MESH:C000657245
555 1779-1787 Disease denotes COVID-19 MESH:C000657245
556 1800-1809 Disease denotes pneumonia MESH:D011014
557 2365-2385 Disease denotes respiratory distress MESH:D012128
558 2403-2423 Disease denotes SARS-CoV-2 infection MESH:C000657245
559 2867-2875 Disease denotes COVID-19 MESH:C000657245

LitCovid-PD-HP

Id Subject Object Predicate Lexical cue hp_id
T36 49-74 Phenotype denotes cytokine release syndrome http://purl.obolibrary.org/obo/HP_0033041
T37 321-334 Phenotype denotes hyperglycemia http://purl.obolibrary.org/obo/HP_0003074
T38 592-601 Phenotype denotes pneumonia http://purl.obolibrary.org/obo/HP_0002090
T39 1800-1809 Phenotype denotes pneumonia http://purl.obolibrary.org/obo/HP_0002090
T40 2365-2385 Phenotype denotes respiratory distress http://purl.obolibrary.org/obo/HP_0002098
T41 2887-2912 Phenotype denotes cytokine release syndrome http://purl.obolibrary.org/obo/HP_0033041

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T134 0-124 Sentence denotes In regard to management of ARDS with evidence of cytokine release syndrome, several adjunctive therapies have been proposed.
T135 125-224 Sentence denotes The rationale for the use of corticosteroids is to reduce host inflammatory responses in the lungs.
T136 225-495 Sentence denotes The potential harm, such as delayed viral clearance, increased risk of secondary infection, and hyperglycemia episodes, have led to caution in their routine use in COVID-19 patients unless the patient had other conditions for which these are indicated [3,4,18,19,20,21].
T137 496-682 Sentence denotes However, in observational and randomized studies focused on hospitalized patients with COVID-19 pneumonia, the administration of corticosteroids reduced the risk of mortality [25,26,27].
T138 683-848 Sentence denotes Based on this fact, a recently published guideline suggested using 40 mg methylprednisolone intravenously for 10 days in patients with severe COVID-19 and ARDS [22].
T139 849-919 Sentence denotes In our study, corticosteroids were included in 87.7% of the protocols.
T140 920-1122 Sentence denotes Methylprednisolone was the most frequently included corticosteroid in the protocols (13/15 protocols) with high-dose regimens (≥1 mg/kg/day) and a variable duration of treatment (between 3 and 10 days).
T141 1123-1263 Sentence denotes High-dose dexamethasone (20 or 40 mg) was included in 53.3% of the protocols and prednisone in just one protocol (40 mg per day for 5 days).
T142 1264-1420 Sentence denotes Monoclonal antibodies targeting key inflammatory citokines or other aspects of the innate immune response are another potential treatment for COVID-19 [28].
T143 1421-1536 Sentence denotes Tocilizumab, an anti-interleukin 6 receptor antibody, has been used in small studies with early reports of success.
T144 1537-1678 Sentence denotes A dose of 400 mg was associated with clinical improvements and successful discharge, with most patients only receiving a single dose [29,30].
T145 1679-1902 Sentence denotes Several randomized clinical trials on tocilizumab, either alone or in combination, in patients with COVID-19 with severe pneumonia are underway, and its use was included in the Chinese national treatment guidelines [30,31].
T146 1903-2112 Sentence denotes Likewise, tocilizumab was recommended in all protocols in Andalusian hospitals; the protocols indicate a single dose of 400 mg or 600 mg, according to body weight, and a second dose 12-24 h later, if required.
T147 2113-2252 Sentence denotes Although tocilizumab is a promising therapy, the data currently available are still too limited to draw any conclusion about its viability.
T148 2253-2481 Sentence denotes Anakinra, an interleukin 1 receptor antagonist, has also been proposed in order to reduce hyperinflammation and respiratory distress in patients with SARS-CoV-2 infection, but here, too, limited evidence has been published [32].
T149 2482-2741 Sentence denotes In this study, less than half of the protocols included anakinra in their recommendations, and six different regimens were described with significant differences in dosage (ranging from 100 to 400 mg per day) and duration of treatment (between 3 and 10 days).
T150 2742-2917 Sentence denotes Other monoclonal antibodies, immunomodulatory agents, and immunoglobulin therapy are in clinical trials for the treatment of COVID-19-associated cytokine release syndrome [3].